Durysta (bimatoprost implant)

Covered for adults (≥18) with open‑angle glaucoma or ocular hypertension to reduce IOP when they have inadequate efficacy or severe adverse events to at least two prostaglandin ophthalmic agents and to at least two ophthalmic products from two different pharmacologic classes; excluded for patients <18 and for re‑treatment of an eye previously treated with Durysta. Authorization requires documentation of those failed/intolerant trials, prescription by or in consultation with an ophthalmologist, and is limited to one implant per treated eye (maximum two implants per patient; approval for one dose).

"Durysta (bimatoprost implant) is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension."

Sign up to see full coverage criteria, indications, and limitations.